{"id":954637,"date":"2026-04-24T16:03:16","date_gmt":"2026-04-24T20:03:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\/"},"modified":"2026-04-24T16:03:16","modified_gmt":"2026-04-24T20:03:16","slug":"compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\/","title":{"rendered":"Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2\/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"margin-bottom:12pt\">\n          <em>Webcast scheduled for Monday, April 27, 2026 at 8:00am ET.<\/em><\/p>\n<\/li>\n<\/ul>\n<p>BOSTON, April  24, 2026  (GLOBE NEWSWIRE) &#8212; Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Monday, April 27, 2026 at 8:00am ET to review topline secondary endpoints from its Phase 2\/3 COMPANION-002 clinical study assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC).\u00a0<\/p>\n<p>\n        <strong>Conference Call and Webcast Presentation: <\/strong>\n      <\/p>\n<p>Date and Time: Monday, April 27, 2026 at 8:00am ET<\/p>\n<p>Toll Free: 1-877-407-9716<\/p>\n<p>International: 1-201-493-6779<\/p>\n<p>Conference ID: 13760371<\/p>\n<p>Webcast Presentation: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FnSTiMamohYKZ8YUDhHtRTCZD1FBGdTvjrDnwx5vlYGiaXnmfiqb7fPNXo-tsK8TTMl4Fj8PDBGxhMFP-jOhlIIIJk7dAaBDBQtEavEPU0ZC48aRf-qJwfkIhrdS7oRQeNa9rad_pZsaokwY94s18Mw1301K8bZeeg9iwWCUo28NlWIlJhbP6y-vF4xxlXBMqzLVCXCTtlr_JHNqiXvCPNhZs3394W2j3giMHaGr0bk54OCoLH2Qd3Y1F43hQPiZWFNL-eiOwBWIGa6WI0mSBCg-n5sqoHbVoJyJWypOghx3wCUv5WJEOnPJeeGTMc8sQtwVe6eRAGxu8sUG8QyDLL2F6KIWO-GslMV4b9WIW206SpeQfeJlB3VUcc49Sh_OAjD0yX4ZNCITYV2Y_ClTAdTDNqqMn_VfU8ukt40ks9f7M9gSh6wlsvrm9Ygo-nF5AQE-hrlG3rgeFcNdwPxDD1caiNkbG2WW4-S5ImSRl0EVbtPT1152_lHuFvQ4zefTV8vccSrsvyeGA4Z1KBnRXrryN6q0pkm9IEe1Lc7bfQbORr-W1d5S2u1V4PsDgCOJY_2zIDqEr0Ob_1eiieZTpAhXpQvos45zGqDdT-T1GAhZaiWi_sZYC58tYjOhauF0bZQzuXDlaeXgJvhanV2kL8uTYbS-e0N2nUn4zumHYUvPkRajvjRwiI6O56prAspP0wLspVXhA5lD1ooRO4GYQSkfNgGFnL58JxPagCwD35G08e6p92g_tTo3dUF0MSA0xJCLSDERIGMNTkm9BTPRaA==\" rel=\"nofollow\" target=\"_blank\">https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1761459&amp;tp_key=efc315f5a6<\/a><\/p>\n<p>A replay of the webcast and accompanying presentation will be available, for 90 days, following the event on the \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=37QjlwtDyFpBqNUPAs6MiQg0e3jyPXoq94Tr2l3r_Q7kHKnuKY5QXy4r8HTfzX5Q2t0jNtV_VzQFqKha4bjFzhmLZ_aQBjtzTI6ntjcvIaROHxYq2KfE1g-ikFU2QU80\" rel=\"nofollow\" target=\"_blank\">Events<\/a>\u201d page under the Investors section of the Company\u2019s website.<\/p>\n<p>\n        <strong>About Compass Therapeutics<\/strong><br \/>\n        <br \/>Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, MA. Compass is a clinical-stage, oncology-focused biopharmaceutical company discovering and developing proprietary antibody-based therapeutics to treat multiple diseases. The company\u2019s scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. Compass has a robust pipeline of novel product candidates designed to target multiple key biological pathways to drive an effective anti-tumor response, including angiogenesis modulation, immune activation within the tumor microenvironment, and reduction of tumor-driven immunosuppression. The company is advancing discovery candidates through clinical development to commercial-stage assets. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TRoeh4ERyMBSzYQwyR8j7Ms3qnpts6RZeCOYHaU6bbx-tQHlM6gTw0_FrxaVnCtHaD9rFhJN5k-0KQHp-6gJBIiJIXc7Q6UK7jDzk27PjS_VQ8DYF2qDGnYlrpmJAOLJ\" rel=\"nofollow\" target=\"_blank\">www.compasstherapeutics.com<\/a>.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CJq9qy9tJN6KSI6d9mP27SZprQiDuBvocTjlaG8Ta8QhkxpbFmpenUaszVX34jrerlNBsm-iZKkW9aDHAXkLhk0G5Mkhpjk8VX_CmvI49vZ9FZDYe1xRmGyr0aXSmUGpyxCEJAi6hiHWLFuiZLCLat9QC45kGTKExyVlmioo6Q0Bu6S8-y1asTYFxlRWE5WEjNg_9-VyX7kL6hDYHEGevQvVeUTBe0xieVcom1phGcTJQx-gVvQQ0-6FbuRmVRGbAhtKJ5uauu8XBech9LLGQNYjplKa8cGai3B9qlDK-I9Vwz_h5xejuwdoWGX3Svx7\" rel=\"nofollow\" target=\"_blank\">ir@compasstherapeutics.com<\/a>\n      <\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Anna Gifford, Chief of Staff<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XWiTtjClzK6TCAJWug4D3bVx5-DfX9lNRGtYVx6KLPsE5E_VzHb6q3iAOsLiX4YC-Dk7o0hqJ881PRSmtoAAmtApJvFMze28_tAZGGrETuhMMPSHdqh7T5SHaqWzgZq2gjZO5NDgHn6BByymKHOsQFs9rQi3IZA4xrGwQ5jX31y3V7eOcNwfN0pmp3aKizt7Q2Zay-6zMo0sP5FNluuzXofxc64PEnHoQKVgwdqNimECbb5gKHhFF-cALaEW7OivoGtEGTmjJDAMRI1tyPDKAvjGSIP86LUyvuxyAxKPBb6SRHPaWyEJFbfgWkJ3sPtF\" rel=\"nofollow\" target=\"_blank\">media@compasstherapeutics.com<\/a><br \/>617-500-8099\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NjU3OCM3NTU0NTY5IzIyMDI0MjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MWFhNGQ2ZWItNWQ5My00MmU1LWI3MmEtMDA4NzY0MTU1MjdjLTEyMTM5NzUtMjAyNi0wNC0yNC1lbg==\/tiny\/Compass-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Webcast scheduled for Monday, April 27, 2026 at 8:00am ET. BOSTON, April 24, 2026 (GLOBE NEWSWIRE) &#8212; Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Monday, April 27, 2026 at 8:00am ET to review topline secondary endpoints from its Phase 2\/3 COMPANION-002 clinical study assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC).\u00a0 Conference Call and Webcast Presentation: Date and Time: Monday, April 27, 2026 at 8:00am ET Toll Free: 1-877-407-9716 International: 1-201-493-6779 Conference ID: 13760371 Webcast Presentation: https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1761459&amp;tp_key=efc315f5a6 A replay of the webcast and accompanying presentation will be available, for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2\/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-954637","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2\/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2\/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Webcast scheduled for Monday, April 27, 2026 at 8:00am ET. BOSTON, April 24, 2026 (GLOBE NEWSWIRE) &#8212; Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Monday, April 27, 2026 at 8:00am ET to review topline secondary endpoints from its Phase 2\/3 COMPANION-002 clinical study assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC).\u00a0 Conference Call and Webcast Presentation: Date and Time: Monday, April 27, 2026 at 8:00am ET Toll Free: 1-877-407-9716 International: 1-201-493-6779 Conference ID: 13760371 Webcast Presentation: https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1761459&amp;tp_key=efc315f5a6 A replay of the webcast and accompanying presentation will be available, for &hellip; Continue reading &quot;Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2\/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-24T20:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NjU3OCM3NTU0NTY5IzIyMDI0MjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2\\\/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer\",\"datePublished\":\"2026-04-24T20:03:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\\\/\"},\"wordCount\":284,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NjU3OCM3NTU0NTY5IzIyMDI0MjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\\\/\",\"name\":\"Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2\\\/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NjU3OCM3NTU0NTY5IzIyMDI0MjI=\",\"datePublished\":\"2026-04-24T20:03:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NjU3OCM3NTU0NTY5IzIyMDI0MjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NjU3OCM3NTU0NTY5IzIyMDI0MjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2\\\/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2\/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2\/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer - Market Newsdesk","og_description":"Webcast scheduled for Monday, April 27, 2026 at 8:00am ET. BOSTON, April 24, 2026 (GLOBE NEWSWIRE) &#8212; Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Monday, April 27, 2026 at 8:00am ET to review topline secondary endpoints from its Phase 2\/3 COMPANION-002 clinical study assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC).\u00a0 Conference Call and Webcast Presentation: Date and Time: Monday, April 27, 2026 at 8:00am ET Toll Free: 1-877-407-9716 International: 1-201-493-6779 Conference ID: 13760371 Webcast Presentation: https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1761459&amp;tp_key=efc315f5a6 A replay of the webcast and accompanying presentation will be available, for &hellip; Continue reading \"Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2\/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-24T20:03:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NjU3OCM3NTU0NTY5IzIyMDI0MjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2\/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer","datePublished":"2026-04-24T20:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\/"},"wordCount":284,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NjU3OCM3NTU0NTY5IzIyMDI0MjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\/","name":"Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2\/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NjU3OCM3NTU0NTY5IzIyMDI0MjI=","datePublished":"2026-04-24T20:03:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NjU3OCM3NTU0NTY5IzIyMDI0MjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NjU3OCM3NTU0NTY5IzIyMDI0MjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2\/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/954637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=954637"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/954637\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=954637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=954637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=954637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}